GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
765
c/t2dglp1·posted 23 days ago by u/camila_vasquez

is it normal to get early fullness at week 88

Caution Slow Clap ×3

is it normal to get early fullness at week 88, logged the same way every week so the comparison is at least internally fair.

Postprandial excursions typically respond earlier than fasting glucose, so the sequence people observe is not a sign that something is not working.

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

1,169 up / 404 down74% upvoted21 commentsid 1pyq1r6 Jul 2026

21 comments

18 in this archive, depth 4

best — the order this archive was captured in

u/marit_mwangi67 points·23 days ago

Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.

replysharereportpermalink
u/chidi_abubakar20 points·22 days ago

Variability dropped before the average did, which was visible on the sensor and invisible on the lab result.

replysharereportpermalink
u/arne_amankwah60 points·22 days ago·edited

Sensor accuracy varies across wear, and readings on the first day are the least reliable. Calibration practice and compression artefacts explain many alarming single values.

replysharereportpermalink
u/step_count_stan70 points·22 days ago

Disagree — that is an obesity trial endpoint and this thread is about glycaemic control.

replysharereportpermalink
u/osman_ferrari49 points·22 days ago

The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.

replysharereportpermalink
u/freya_onwuka31 points·22 days ago

Right, and the diabetes programmes report glycaemic endpoints. Quoting an obesity trial result here is answering a different question.

replysharereportpermalink
u/lyophile_lou10 points·21 days ago

nothing here replaces the person managing your diabetes

replysharereportpermalink
u/a1c_arcMOD19 points·21 days ago

Retitled — the original quoted an obesity endpoint as a glycaemic one.

replysharereportpermalink
u/milan_chukwu13 points·21 days ago

That A1c change is inside the assay’s variability and the interval you measured over is too short.

replysharereportpermalink
u/santiago_rasmussen4 points·21 days ago

This. Hypoglycaemia risk in this class is driven mostly by the other agents in the regimen.

replysharereportpermalink
u/cormac_danquah19 points·21 days ago

Kept fingersticks alongside the sensor for two weeks to sanity-check it. Worth doing once.

replysharereportpermalink
u/thandi_solberg8 points·21 days ago

sensor accuracy varies and the first day of a sensor is the worst

replysharereportpermalink
[removed]8 points·21 days ago

[removed by moderator]

replysharereportpermalink
u/bianca_demir2 points·21 days ago

metformin and an incretin agonist are not in competition

replysharereportpermalink
u/stablecoin_steve13 points·21 days ago

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

replysharereportpermalink
u/gentle_correctionnice about it9 points·21 days ago

Certain conditions affect A1c independently of glycaemia.

Agreed, and the glucose-dependence point is the reason the risk profile reads the way it does.

replysharereportpermalink
u/tomas_kimani20 points·23 days ago

Agreed on variability. Two people with the same average can have completely different days.

replysharereportpermalink
u/meal_prep_mira17 points·22 days ago·edited

I would not compare your numbers to that population. Different baseline, different regimen, different trial.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/t2dglp1

Type 2 diabetes as the original indication: A1c trajectories, CGM traces, hypoglycaemia risk when stacked with sulfonylureas or insulin, metformin combinations, and why the weight-loss conversation sometimes drowns out the glycaemic one.

36kmembers
62submissions
Jun 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/t2dglp1 rules
  1. Insulin and sulfonylurea interactions are a real hypo risk. Do not hand-wave them.
  2. Post A1c with units and the assay date.
  3. No medication-stopping advice. Ever.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.